Relay Therapeutics (RLAY) Interest Coverage Ratio (2019 - 2026)
Relay Therapeutics (RLAY) posted quarterly Interest Coverage Ratio of 215.32 for Q1 2026, down 131.12% year-over-year from 691.81 in Q1 2025, and up 97.87% quarter-over-quarter from 10105.0 in Q4 2025.
Relay Therapeutics (RLAY) Interest Coverage Ratio (2019 - 2026) Analysis & Trends
Relay Therapeutics (RLAY) has reported Interest Coverage Ratio for 8 consecutive years, with 215.32 the latest figure, recorded in Q1 2026.
- In Q1 2026, Interest Coverage Ratio fell 131.12% year-over-year to 215.32; the TTM figure through Mar 2026 stood at 812.21 (down 101.63% YoY), while the FY2025 annual figure was 0.63, up 26.94% from the prior year.
- Interest Coverage Ratio rose to 215.32 in Q1 2026 per RLAY's latest filing, from 10105.0 in the prior quarter.
- Across five years, Interest Coverage Ratio topped out at 0.2 in Q4 2024 and bottomed at 10105.0 in Q4 2025.
- Historically, Interest Coverage Ratio has averaged 670.41 across 5 years, with a median of 21.73 in 2023.
- Annual changes were most pronounced in 2022 — Interest Coverage Ratio jumped 99.73% — and 2025, when it tumbled 5136042.51%.
- Relay Therapeutics' Interest Coverage Ratio stood at 9.61 in 2022, then surged by 49.27% to 4.88 in 2023, then surged by 95.97% to 0.2 in 2024, then sank by 5136042.51% to 10105.0 in 2025, then soared by 97.87% to 215.32 in 2026.
- Business Quant data shows RLAY's Interest Coverage Ratio at 215.32 in Q1 2026, 10105.0 in Q4 2025, and 336.36 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.84 |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 24.64 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -0.19 |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.18 |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.01 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 0.61 |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 2.82 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.08 |
| 10 | Relay Therapeutics | 4.34 Bn | 4.34 Bn | - | -56.34 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -56.34 |
| Mar 31, 2026 | -215.32 |
| Dec 31, 2025 | -10,105.00 |
| Sep 30, 2025 | -336.36 |
| Jun 30, 2025 | -18.13 |
| Mar 31, 2025 | -93.16 |
| Dec 31, 2024 | -0.20 |
| Sep 30, 2024 | -323.39 |
| Jun 30, 2024 | -74.63 |
| Mar 31, 2024 | -69.72 |
| Dec 31, 2023 | -4.88 |
| Sep 30, 2023 | -21.73 |
| Jun 30, 2023 | -17.44 |
| Mar 31, 2023 | -15.97 |
| Dec 31, 2022 | -9.61 |
| Sep 30, 2022 | -78.08 |
| Jun 30, 2022 | -6.54 |
| Mar 31, 2022 | -6.80 |
| Dec 31, 2021 | -16.93 |
| Sep 30, 2021 | -60.99 |